person · Reporting owner

Iwicki Mark T

Disclosed activity across 9 companies

Tapewire entity: 29290
SEC CIK: 0001415537

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Inhibikase Therapeutics, Inc.IKT · Entity 5838	Director · Chief Executive Officer	January 05, 2026	January 07, 2026
Jade Biosciences, Inc.AVTE · Entity 4757	Director	June 05, 2024	June 07, 2024
KALA BIO, Inc.KALA · Entity 7964	Director	October 23, 2025	October 25, 2025
Pulmatrix, Inc.PULM · Entity 8249	Director	January 28, 2021	February 02, 2021
Q32 Bio Inc.QTTB · Entity 5594	Director	June 12, 2026	July 22, 2026
Third Harmonic Bio, Inc.THRD · Entity 76517	Director	August 11, 2025	August 14, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Inhibikase Therapeutics, Inc.

Report date January 05, 2026 · Filed January 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-05	Direct	4,982,706	Reported balance After 2026-01-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-05 · Grant · Acquired 4,982,706 · Balance 4,982,706 F1: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.

Jade Biosciences, Inc.

Report date June 05, 2024 · Filed June 07, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.90 · Expires 2034-06-04	Direct	12,500	Reported balance After 2024-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2024-06-05 · Grant · Acquired 12,500 · Balance 12,500 F1: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 5, 2025 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date.

KALA BIO, Inc.

Report date October 23, 2025 · Filed October 25, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	103,540	Reported balance After 2025-10-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-10-23 · Sale · Disposed 154,894 · Balance 103,540 F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Includes 103,540 unvested RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.78 to $0.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2: Includes 103,540 unvested RSUs.

Pulmatrix, Inc.

Report date January 28, 2021 · Filed February 02, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.47 · Expires 2031-01-28	Direct	15,000	Reported balance After 2021-01-28 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-01-28 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan.

Q32 Bio Inc.

Report date June 12, 2026 · Filed July 22, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.64 · Expires 2036-06-11	Direct	10,826	Reported balance After 2026-06-12 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-06-12 · Grant · Acquired 10,826 · Balance 10,826 F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026. F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.

F2: The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Third Harmonic Bio, Inc.

Report date August 11, 2025 · Filed August 14, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-08-11 transaction · row 1 1 source row Row 1 · 2025-08-11 · Other · Disposed 128,631 · Balance 0 F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer. F2: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer.
Stock OptionSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-08-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-08-11 · Other · Disposed 83,296 · Balance 0 F3: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options. F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction reported is a cancellation of shares of common stock in connection with the dissolution of the Issuer.

F2: The reporting person received a liquidation distribution of $5.35 per share of Common Stock from Issuer.

F3: Represents payment of the liquidation distribution of $5.35 per share less the exercise price of such options.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Aimmune Therapeutics, Inc.

Report date October 10, 2020 · Filed October 14, 2020

Section 16 reporting ended · disclosed 2020-10-14. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-10 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2020-10-10 · Other · Disposed 39,567 · Balance 0
Common Stock, $0.0001 par valueSEC Table I · non-derivative	Direct	Reported balance After 2020-10-13 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2020-10-13 · Disposition to issuer · Disposed 7,840 · Balance 0 F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price"). F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02	Direct	Reported balance After 2020-10-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-10-13 · Disposition to issuer · Disposed 52,421 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.29	Direct	Reported balance After 2020-10-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-10-13 · Disposition to issuer · Disposed 87,368 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.40	Direct	Reported balance After 2020-10-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-10-13 · Disposition to issuer · Disposed 19,755 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.26	Direct	Reported balance After 2020-10-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-10-13 · Disposition to issuer · Disposed 17,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.79	Direct	Reported balance After 2020-10-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-10-13 · Disposition to issuer · Disposed 7,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.90	Direct	Reported balance After 2020-10-13 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-10-13 · Disposition to issuer · Disposed 11,432 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.11	Direct	Reported balance After 2020-10-13 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-10-13 · Disposition to issuer · Disposed 15,398 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of to SPN MergerSub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., ("Nestle"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the "Offer Price").

F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") that was outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option.

Akero Therapeutics, Inc.

Report date December 09, 2025 · Filed December 09, 2025

Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-12-09 transaction · row 1 1 source row Row 1 · 2025-12-09 · Disposition to issuer · Disposed 9,398 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Novo ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a direct or indirect wholly owned subsidiary of Novo. F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2034-06-08	Direct	Reported balance After 2025-12-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-09 · Disposition to issuer · Disposed 26,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.83 · Expires 2033-06-23	Direct	Reported balance After 2025-12-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.13 · Expires 2032-06-02	Direct	Reported balance After 2025-12-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.32 · Expires 2031-06-01	Direct	Reported balance After 2025-12-09 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.20 · Expires 2030-06-01	Direct	Reported balance After 2025-12-09 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-09 · Disposition to issuer · Disposed 13,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2029-04-26	Direct	Reported balance After 2025-12-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-09 · Disposition to issuer · Disposed 70,587 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2029-01-16	Direct	Reported balance After 2025-12-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-09 · Disposition to issuer · Disposed 11,493 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.62 · Expires 2028-10-18	Direct	Reported balance After 2025-12-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-12-09 · Disposition to issuer · Disposed 76,227 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc, a Delaware corporation and a direct or indirect wholly owned subsidiary of Novo ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a direct or indirect wholly owned subsidiary of Novo.

F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of common stock of the Issuer ("Company Common Stock") upon vesting of the Company RSU.

F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive in respect of each such Company RSU (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement), without interest and subject to any withholding taxes.

F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.

Merus N.V.

Report date December 12, 2025 · Filed December 12, 2025

Section 16 reporting ended · disclosed 2025-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2025-12-12 transaction · row 1 1 source row Row 1 · 2025-12-12 · Other · Disposed 73,576 · Balance 0 F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.60 · Expires 2035-05-22	Direct	Reported balance After 2025-12-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-12-12 · Disposition to issuer · Disposed 13,193 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.73 · Expires 2034-05-07	Direct	Reported balance After 2025-12-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-12-12 · Disposition to issuer · Disposed 8,844 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.29 · Expires 2033-06-08	Direct	Reported balance After 2025-12-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-12-12 · Disposition to issuer · Disposed 14,414 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.56 · Expires 2032-05-31	Direct	Reported balance After 2025-12-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-12-12 · Disposition to issuer · Disposed 16,604 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.15 · Expires 2031-05-28	Direct	Reported balance After 2025-12-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-12-12 · Disposition to issuer · Disposed 6,120 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.09 · Expires 2030-06-30	Direct	Reported balance After 2025-12-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-12-12 · Disposition to issuer · Disposed 8,631 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.12 · Expires 2027-05-24	Direct	Reported balance After 2025-12-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-12-12 · Disposition to issuer · Disposed 5,650 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.30 · Expires 2028-07-20	Direct	Reported balance After 2025-12-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-12-12 · Disposition to issuer · Disposed 4,983 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.
Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2029-06-12	Direct	Reported balance After 2025-12-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-12-12 · Disposition to issuer · Disposed 8,500 · Balance 0 F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Filing footnotes · ownership attribution and instrument terms

F1: On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time, including the Shares tendered by the reporting person, in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

F2: This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 31, 2024 Filed Jun 4, 2024 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	7,392	$6.09	$45,017.28	Disclosure SEC source: 0001415889-24-015222 · form4-06032024_080602.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 278,923 F1 · shares: This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 244,256 unvested RSUs. Read SEC document
May 07, 2024 Filed May 9, 2024 20:30 UTC	Merus N.V. MRUS · Entity 70740	GrantShare Option (right to buy) · Derivative	8,844	$0.00 Strike: $48.73	$0.00	Disclosure SEC source: 0000950170-24-057082 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,844 Underlying: Common Shares · 8,844 shares Expires 2034-05-07 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 7, 2024 in 12 equal monthly installments. Read SEC document
March 25, 2024 Filed Mar 27, 2024 21:40 UTC	Q32 Bio Inc. QTTB · Entity 5594	GrantStock Option (Right to Buy) · Derivative	25,534	$0.00 Strike: $16.82	$0.00	Disclosure SEC source: 0000950170-24-037399 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,534 Underlying: Common Stock · 25,534 shares Expires 2034-03-24 F1 · derivative.exercise_date: One-third of the shares underlying this option shall vest and become exercisable on March 25, 2025, with the remainder vesting in twenty-four (24) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document
January 04, 2024 Filed Jan 5, 2024 21:04 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantStock Option (right to buy) · Derivative	64,500	$0.00 Strike: $7.00	$0.00	Disclosure SEC source: 0001415889-24-000769 · form4-01052024_090140.xml · derivative · entry 3 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,500 Underlying: Common Stock · 64,500 shares Expires 2034-01-03 F6 · derivative.exercise_date: This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer. Read SEC document
January 04, 2024 Filed Jan 5, 2024 21:04 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	4,539	$6.73	$30,547.47	Disclosure SEC source: 0001415889-24-000769 · form4-01052024_090140.xml · nonDerivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,315 F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F5 · balance_after: Includes 272,690 unvested RSUs. Read SEC document
January 04, 2024 Filed Jan 5, 2024 21:04 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantCommon Stock	14,300	$0.00	$0.00	Disclosure SEC source: 0001415889-24-000769 · form4-01052024_090140.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 290,854 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027. F2 · balance_after: Includes 287,095 unvested RSUs. Read SEC document
June 23, 2023 Filed Jun 27, 2023 17:39 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $50.83	$0.00	Disclosure SEC source: 0000950170-23-030209 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-06-22 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 23, 2024 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document
June 22, 2023 Filed Jun 24, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantStock Option (right to buy) · Derivative	211,831	$0.00 Strike: $14.56	$0.00	Disclosure SEC source: 0001415889-23-010281 · form4-06232023_080601.xml · derivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,831 Underlying: Common Stock · 211,831 shares Expires 2033-06-21 F3 · derivative.exercise_date: This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter. Read SEC document
June 22, 2023 Filed Jun 24, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantCommon Stock	158,873	$0.00	$0.00	Disclosure SEC source: 0001415889-23-010281 · form4-06232023_080601.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 276,554 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026. F2 · balance_after: Includes 272,795 unvested RSUs. Read SEC document
June 08, 2023 Filed Jun 12, 2023 20:16 UTC	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	14,414	$0.00 Strike: $23.29	$0.00	Disclosure SEC source: 0001209191-23-036268 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,414 Underlying: Common Shares · 14,414 shares Expires 2033-06-08 F1 · derivative.exercise_date: Options vest over a one-year period commencing June 8, 2023 in 12 equal monthly installments. Read SEC document
June 06, 2023 Filed Jun 8, 2023 16:18 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	GrantStock Option (right to buy) · Derivative	16,250	$0.00 Strike: $5.03	$0.00	Disclosure SEC source: 0001209191-23-035382 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 16,250 shares Expires 2033-06-05 F1 · derivative.exercise_date: The option will vest in full on the earlier of (a) June 6, 2024 and (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's provision of service to the Issuer on the vesting date. Read SEC document
June 06, 2023 Filed Jun 8, 2023 22:00 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $16.30	$0.00	Disclosure SEC source: 0001415889-23-009443 · form4-06082023_060603.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2033-06-05 F1 · derivative.exercise_date: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 6, 2024 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	2,268	Not disclosed Strike: $68.50	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 11 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,268 shares Expires 2032-01-03 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F13 · derivative.exercise_date: The canceled option was granted on January 3, 2022 and provided for the purchase of up to 5,670 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 1,512 shares had vested, options to purchase 3,024 shares had been forfeited and options to purchase up to 1,134 shares were unvested assuming maximum level of achievement (options to purchase 756 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	15,499	Not disclosed Strike: $68.50	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 10 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,499 shares Expires 2032-01-03 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F12 · derivative.exercise_date: The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	6,059	Not disclosed Strike: $343.00	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 9 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,059 shares Expires 2031-01-03 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F11 · derivative.exercise_date: The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	7,299	Not disclosed Strike: $192.00	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 8 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,299 shares Expires 2030-01-01 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F10 · derivative.exercise_date: The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	9,199	Not disclosed Strike: $259.50	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 7 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,199 shares Expires 2029-01-01 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F9 · derivative.exercise_date: The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	4,599	Not disclosed Strike: $643.00	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 6 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,599 shares Expires 2028-02-06 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F8 · derivative.exercise_date: The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	1,572	Not disclosed Strike: $750.00	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 5 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,572 shares Expires 2027-07-18 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: The canceled option was granted on July 19, 2017 and provided for vesting over four years with 1/48th of the shares underlying the option vested on August 31, 2017 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	12,195	Not disclosed Strike: $167.00	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 4 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,195 shares Expires 2026-06-17 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: The canceled option was granted on June 17, 2016 and provided for vesting over four years with 1/48th of the shares underlying the option vested on April 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	7,576	Not disclosed Strike: $260.50	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 3 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,576 shares Expires 2025-09-11 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F5 · derivative.exercise_date: The canceled option was granted on September 15, 2015 and provided for vesting over four years with 25% of the shares underlying the option vested on April 8, 2016 and 1/48th of the shares vested at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	Disposition to issuerStock Option (right to buy) · Derivative	5,449	Not disclosed Strike: $167.00	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · derivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,449 shares Expires 2025-06-03 F3 · derivative.exercise_price: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F3 · shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The canceled option was granted on June 4, 2015 and provided for vesting over four years with 1/48th of the shares underlying the option vested on May 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter. F3 · derivative.underlying_shares: The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
May 31, 2023 Filed Jun 3, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantCommon Stock	71,715	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-23-009133 · form4-06022023_080601.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,681 F1 · price: On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 56,873 restricted stock units (the "RSUs") that vest over two years, with 50% of such RSUs vesting on May 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 14,842 RSUs that vest over three years, with 83% of such RSUs vesting on May 31, 2025 and 17% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 113,922 unvested RSUs. Read SEC document
April 14, 2023 Filed Apr 17, 2023 12:26 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	36,632	$0.00 Strike: $7.97	$0.00	Disclosure SEC source: 0001209191-23-024393 · doc4.xml · derivative · entry 4 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 36,632 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vest over a four-year period commencing August 21, 2015. 25% vest after one year and in 36 equal installments thereafter. Read SEC document
April 14, 2023 Filed Apr 17, 2023 12:26 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionShare Option (right to buy) · Derivative	36,944	$0.00 Strike: $6.57	$0.00	Disclosure SEC source: 0001209191-23-024393 · doc4.xml · derivative · entry 3 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 36,944 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a four-year period commencing June 6, 2015. 25% vest after one year and in 36 equal installments thereafter. Read SEC document
April 14, 2023 Filed Apr 17, 2023 12:26 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	36,632	$7.97	$291,957.04	Disclosure SEC source: 0001209191-23-024393 · doc4.xml · nonDerivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,576 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Exercise price is denominated in Euros. Exchange rate of 1.1057 used to convert to USD. Read SEC document
April 14, 2023 Filed Apr 17, 2023 12:26 UTC	Merus N.V. MRUS · Entity 70740	Exercise / conversionCommon Shares	36,944	$6.57	$242,722.08	Disclosure SEC source: 0001209191-23-024393 · doc4.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Exercise price is denominated in Euros. Exchange rate of 1.1057 used to convert to USD. Read SEC document
March 14, 2023 Filed Mar 16, 2023 00:00 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantStock Option (Right to Buy) · Derivative	1,512	$0.00 Strike: $68.50	$0.00	Disclosure SEC source: 0001415889-23-004973 · form4-03152023_080301.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,512 Underlying: Common Stock · 1,512 shares Expires 2032-01-03 F1 · derivative.exercise_date: On January 3, 2022, the Reporting Person was granted an option to purchase up to 5,670 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters. F2 · derivative.exercise_date: On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 1,512 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 1,134 shares of common stock underlying the option. Read SEC document
March 06, 2023 Filed Mar 8, 2023 17:02 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	GrantEmployee Stock Option (right to buy) · Derivative	13,667	Not disclosed Strike: $4.20	Not disclosed	Disclosure SEC source: 0001209191-23-017237 · doc4.xml · derivative · entry 4 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
March 06, 2023 Filed Mar 8, 2023 17:02 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	13,667	Not disclosed Strike: $17.83	Not disclosed	Disclosure SEC source: 0001209191-23-017237 · doc4.xml · derivative · entry 3 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F3 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
March 06, 2023 Filed Mar 8, 2023 17:02 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	GrantEmployee Stock Option (right to buy) · Derivative	35,413	Not disclosed Strike: $4.20	Not disclosed	Disclosure SEC source: 0001209191-23-017237 · doc4.xml · derivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,413 Underlying: Common Stock · 35,413 shares Expires 2032-02-16 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on February 17, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
March 06, 2023 Filed Mar 8, 2023 17:02 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	Disposition to issuerEmployee Stock Option (right to buy) · Derivative	35,413	Not disclosed Strike: $9.22	Not disclosed	Disclosure SEC source: 0001209191-23-017237 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,413 shares Expires 2032-02-16 F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on March 6, 2023, and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on February 17, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document
January 04, 2023 Filed Jan 7, 2023 01:00 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	198	$28.54	$5,650.92	Disclosure SEC source: 0001415889-23-000636 · form4-01062023_080102.xml · nonDerivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,966 F3 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.71, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F5 · balance_after: Includes 42,207 unvested RSUs. Read SEC document
January 04, 2023 Filed Jan 7, 2023 01:00 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantCommon Stock	41,700	$0.00	$0.00	Disclosure SEC source: 0001415889-23-000636 · form4-01062023_080102.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,164 F1 · security: Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026. F2 · balance_after: Includes 42,714 unvested RSUs. Read SEC document
October 26, 2022 Filed Oct 27, 2022 16:55 UTC	Third Harmonic Bio, Inc. THRD · Entity 76517	GrantStock Option (right to buy) · Derivative	13,667	$0.00 Strike: $17.83	$0.00	Disclosure SEC source: 0001209191-22-054728 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,667 Underlying: Common Stock · 13,667 shares Expires 2032-10-25 F1 · derivative.exercise_date: The option vests over a 8-month period: 1/8th on October 26, 2022, after which 1/8th of the total shares vest monthly, subject to continued service through each vesting date. Read SEC document
October 26, 2022 Filed Oct 28, 2022 20:15 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	561	$6.52	$3,657.72	Disclosure SEC source: 0001415889-22-010878 · form4-10282022_041001.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,464 F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.62, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 1,014 unvested RSUs. F4 · balance_after: The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022. Read SEC document
June 27, 2022 Filed Jun 30, 2022 00:09 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	7,975	$0.37	$2,950.75	Disclosure SEC source: 0001415889-22-007059 · form4-06292022_050622.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,183 F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020. F2 · balance_after: Includes 139,819 unvested RSUs. Read SEC document
June 21, 2022 Filed Jun 22, 2022 21:00 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	GrantStock Option (Right to Buy) · Derivative	12,500	$0.00 Strike: $12.26	$0.00	Disclosure SEC source: 0001493152-22-017510 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2032-06-20 F1 · derivative.exercise_date: The shares subject to this option will vest and become exercisable in full on the earlier of (i) June 21, 2023 or (ii) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document
June 02, 2022 Filed Jun 3, 2022 16:06 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $8.13	$0.00	Disclosure SEC source: 0000899243-22-020941 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document
May 31, 2022 Filed Jun 2, 2022 20:05 UTC	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	16,604	$0.00 Strike: $18.56	$0.00	Disclosure SEC source: 0000899243-22-020664 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,604 Underlying: Common Shares · 16,604 shares Expires 2032-05-31 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 31, 2022 in 12 equal monthly installments. Read SEC document
January 04, 2022 Filed Jan 6, 2022 01:00 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	9,518	$1.30	$12,373.40	Disclosure SEC source: 0001415889-22-000402 · form4-01052022_080111.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,158 F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 164,599 unvested RSUs. Read SEC document
January 03, 2022 Filed Jan 6, 2022 01:00 UTC	KALA BIO, Inc. KALA · Entity 7964	GrantStock Option (right to buy) · Derivative	775,000	$0.00 Strike: $1.37	$0.00	Disclosure SEC source: 0001415889-22-000402 · form4-01052022_080111.xml · derivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 775,000 Underlying: Common Stock · 775,000 shares Expires 2032-01-03 F4 · derivative.exercise_date: This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter. Read SEC document
October 26, 2021 Filed Oct 29, 2021 00:01 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	27,598	$1.80	$49,676.40	Disclosure SEC source: 0001415889-21-005009 · form4-10282021_051046.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,676 F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on June 25, 2020. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 189,930 unvested RSUs. Read SEC document
June 29, 2021 Filed Jul 1, 2021 22:33 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	GrantStock Option (Right to Buy) · Derivative	42,200	$0.00 Strike: $14.00	$0.00	Disclosure SEC source: 0001104659-21-088381 · tm2121189-6_4seq1.xml · derivative · entry 3 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,200 Underlying: Common Stock · 42,200 shares Expires 2031-06-28 F5 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 29, 2021. Read SEC document
June 28, 2021 Filed Jun 29, 2021 21:25 UTC	KALA BIO, Inc. KALA · Entity 7964	SaleCommon Stock	7,586	$5.77	$43,771.22	Disclosure SEC source: 0001415889-21-003256 · form4-06292021_050601.xml · nonDerivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,274 F1 · shares: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020. F2 · balance_after: Includes 279,080 unvested RSUs. Read SEC document
June 01, 2021 Filed Jun 3, 2021 17:58 UTC	Akero Therapeutics, Inc. AKRO · Entity 71984	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $26.32	$0.00	Disclosure SEC source: 0001104659-21-076501 · tm2118278-7_4seq1.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document
May 28, 2021 Filed Jun 2, 2021 20:10 UTC	Merus N.V. MRUS · Entity 70740	GrantShare option (right to buy) · Derivative	6,120	$0.00 Strike: $21.15	$0.00	Disclosure SEC source: 0000899243-21-021547 · doc4.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,120 Underlying: Common Shares · 6,120 shares Expires 2031-05-28 F1 · derivative.exercise_date: Options vest over a one-year period commencing May 28, 2021 in 12 equal monthly installments. Read SEC document
April 02, 2021 Filed Jul 1, 2021 22:33 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	GrantStock Option (Right to Buy) · Derivative	76,747	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001104659-21-088381 · tm2121189-6_4seq1.xml · derivative · entry 2 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,747 Underlying: Common Stock · 76,747 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F4 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on July 4, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document
April 02, 2021 Filed Jul 1, 2021 22:33 UTC	Jade Biosciences, Inc. AVTE · Entity 4757	GrantStock Option (Right to Buy) · Derivative	39,550	$0.00 Strike: $2.14	$0.00	Disclosure SEC source: 0001104659-21-088381 · tm2121189-6_4seq1.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,550 Underlying: Common Stock · 39,550 shares Expires 2031-04-01 F1 · derivative.exercise_price: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F2 · kind: This transaction occurred prior to the Issuer's initial public offering, and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F1 · shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F3 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vested on March 12, 2021. F1 · derivative.underlying_shares: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. F1 · balance_after: On June 22, 2021, the Issuer completed a one-for-3.1060103 reverse stock split of the Issuer's Common Stock (the "Reverse Split"). This amount has been adjusted to give effect to the Reverse Split. Read SEC document
January 28, 2021 Filed Feb 2, 2021 02:45 UTC	Pulmatrix, Inc. PULM · Entity 8249	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $1.47	$0.00	Disclosure SEC source: 0001493152-21-002329 · ownership.xml · derivative · entry 1 Iwicki Mark T · CIK 0001415537 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The shares underlying this stock option will vest and become exercisable in forty-eight (48) equal monthly installments beginning on the first monthly anniversary of the date of grant, with the first tranche vesting on January 28, 2021, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.